Financial report
For the six months ended 30 June 2021 (unaudited)
|
|
|
|
|
|
kEUR |
Note |
H1 2021 |
H1 2020 |
|
|
|
|
|
|
Result for the period |
|
24,623 |
7,831 |
|
|
|
|
|
|
Other comprehensive income to be reclassified to profit or loss in subsequent periods: |
|
|
|
|
Exchange differences on translation of foreign operations, net of tax |
|
1,553 |
-299 |
|
Net other comprehensive income to be reclassified to profit or loss in subsequent periods |
|
1,553 |
-299 |
|
|
|
|
|
|
Other comprehensive income not to be reclassified to profit or loss in subsequent periods: |
|
|
|
|
Remeasurement gains (losses) on defined benefit plans |
|
3,877 |
-132 |
|
Income tax effect |
|
-889 |
37 |
|
|
|
|
|
|
Net other comprehensive income not to be reclassified to profit or loss in subsequent periods |
|
2,988 |
-95 |
|
Other comprehensive result for the period, net of taxes |
|
4,541 |
-394 |
|
Total comprehensive result for the period, net of taxes |
|
29,164 |
7,437 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
29,164 |
7,437 |